Skip to main navigation

Main Corporate Nav

  • About Us
    • Overview
    • Leadership
    • Board of Directors
    • Partnering
    • Our History
  • Pipeline
    • Overview
    • AL Amyloidosis & Birtamimab
    • Parkinson's Disease & Prasinezumab
    • ATTR Amyloidosis & PRX004
    • Alzheimer's Disease
    • Pioneering Neuroscience
    • Publications
  • Clinical Trials
    • Overview
    • Birtamimab Phase 3 Study
    • Prasinezumab Phase 2 Study
    • PRX004 Phase 1 Study
    • Expanded Acces Policy
  • Investors
    • Overview
    • Press Releases
    • Events & Presentations
    • Financial & Filings
    • Corporate Governance
    • Stock information
    • Analyst Coverage
  • Careers
    • Overview
    • Our Values
    • Compensation & Benefits
    • Opportunities
    • Public House
  • Contact Us
    About Us
    • Leadership
    • Board of Directors
    • Partnering
    • Our History
    • About Us
      • Management
      • Board of Directors
      • Partnering
      • Our History
    • Pipeline
      • Parkinson’s Disease & prasinezumab
      • ATTR Amyloidosis & PRX004
      • Alzheimer’s Disease
      • Neuroscience Discovery Programs
      • Publications
    • Clinical Trials
      • Prasinezumab Phase 2 Study
      • PRX004 Phase 1 Study
      • Expanded Access Policy
    • Investors
      • Press Releases
      • Events & Presentations
      • Financials & Filings
      • Corporate Governance
      • Stock Information
      • Analyst Coverage
    • Careers
      • Our Values
      • Compensation & Benefits
      • Opportunities
      • Public House
    • Contact Us
    • Menu Menu

    Event Details

    Investor Relations

    • Overview
    • Press Releases
    • Events & Presentations
    • Financials & Filings
      • SEC Filings
      • Quarterly Results
      • Key Ratios
      • Irish Statutory Financial Statements
    • Corporate Governance
      • Committee Composition
    • Stock Information
    • Analyst Coverage

    Shareholder Tools

    Oppenheimer 31st Annual Healthcare Conference

    Mar 17, 2021 at 10:00 AM EDT

    Listen to webcast

    Main Corporate Nav

    • About Us
      • Overview
      • Leadership
      • Board of Directors
      • Partnering
      • Our History
    • Pipeline
      • Overview
      • AL Amyloidosis & Birtamimab
      • Parkinson's Disease & Prasinezumab
      • ATTR Amyloidosis & PRX004
      • Alzheimer's Disease
      • Pioneering Neuroscience
      • Publications
    • Clinical Trials
      • Overview
      • Birtamimab Phase 3 Study
      • Prasinezumab Phase 2 Study
      • PRX004 Phase 1 Study
      • Expanded Acces Policy
    • Investors
      • Overview
      • Press Releases
      • Events & Presentations
      • Financial & Filings
      • Corporate Governance
      • Stock information
      • Analyst Coverage
    • Careers
      • Overview
      • Our Values
      • Compensation & Benefits
      • Opportunities
      • Public House
    • Contact Us

    2021© Prothena | Terms of Use | Privacy Policy

    Scroll to top